Search This Blog

Monday, June 23, 2025

Amgen Expands MariTide Development Plans After Weight-Loss Trial

 Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea.

The drug demonstrated 20% average weight loss among people with obesity without Type 2 diabetes, and 17% among people with both obesity and Type 2 diabetes. Weight loss hadn't plateaued by 52 weeks, indicating patients could potentially lose more weight, Amgen said Monday.

MariTide also showed sustained reduction in hemoglobin A1c.

The trial results are informing a third phase of trials, which will last 72 weeks and will evaluate the safety, efficacy and tolerability of MariTide for overweight and obese patients with and without Type 2 diabetes.

Amgen also expects to start a Phase 3 study for atherosclerotic cardiovascular disease and heart failure, as well as a Phase 3 study for obstructive sleep apnea in 2025.

https://www.morningstar.com/news/dow-jones/202506236489/amgen-expands-maritide-development-plans-after-successful-weight-loss-trial

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.